University of Virginia Installs First Two TomoTherapy(R) TomoHD(TM) Systems in U.S.
18 Avril 2011 - 2:00PM
Marketwired
TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced
radiation therapy solutions for the treatment of cancer and other
diseases, today announced that two of the first TomoTherapy®
TomoHD™ treatment systems in the United States were purchased and
installed by the University of Virginia Health System. Clinicians
began using one of the TomoHD™ treatment systems to treat patients
in early April at the newly opened Emily Couric Clinical Cancer
Center on University of Virginia's flagship campus in
Charlottesville, Va. The second system was installed and is
operated in a partnership between the University of Virginia Health
System and the Culpeper Regional Hospital Radiation Oncology
Service in Culpeper, Va.
"We have extensive experience with the use of TomoTherapy
technology here at University of Virginia, and the evolution to the
TomoHD treatment system is a natural extension of our
capabilities," said Paul Read, M.D., Ph.D., vice chair of
University of Virginia's Department of Radiation Oncology. "By
installing a TomoHD system at our Charlottesville campus, we will
have more flexibility to treat complex cancers -- such as head and
neck tumors -- with precision using the TomoTherapy platform's
image-guided radiation therapy capabilities. And for our partner at
the community cancer center in Culpeper, TomoHD is an ideal
multipurpose device for delivering radiation therapy to patients
with common cancers, such as those of the breast or prostate, who
don't want to travel great distances for cutting-edge care."
According to Stan Benedict, Ph.D., chief of Medical Physics,
University of Virginia, installation of the TomoHD treatment
systems was highly efficient compared to traditional radiation
therapy devices. "We were able to get up and running with the
TomoHD systems in one-third of the amount of time it takes with a
conventional linear accelerator. This means patients can benefit
from our investment in state-of-the-art cancer care in a much
shorter timeframe," said Benedict.
The Emily Couric Clinical Cancer Center opened on April 4 and is
designed to provide patients with state-of-the-art therapies and
comprehensive cancer care. Within a week of the center's opening,
University of Virginia clinicians were treating on average 20
patients a day on the TomoHD system, with a focus on head and neck
tumors and hypofractionated courses of radiation for prostate
cancer.
The TomoHD treatment system expands on TomoTherapy's proven
technology, which integrates daily CT imaging with precise
radiation delivery capabilities. By combining TomoHelical™ and
TomoDirect™ delivery modes, the TomoHD treatment system gives
clinicians the ability to select the optimal radiation delivery
technique and efficiently treat a wide range of tumors using
advanced image-guided, intensity-modulated radiation therapy
(IG-IMRT).
With the TomoHelical mode of delivery, small "beamlets" of
radiation are delivered in a helical pattern from any point in a
360° radius around the patient. This rotational delivery pattern
enables radiation to be delivered from all angles around a patient,
helping to target dose directly to the tumor while avoiding
critical organs. As a result of this delivery method, patients
often have improved outcomes, fewer side effects and a better
quality of life, compared to traditional radiation therapy
solutions. The TomoDirect delivery mode facilitates a
non-rotational delivery option that enables clinicians to quickly
plan and deliver advanced TomoTherapy radiation treatments with a
series of linear beam paths, rather than a single helical delivery
path, thereby improving efficiency in the treatment of more common
or less complex tumors.
"We are proud to work with The University of Virginia to bring
the benefits of TomoTherapy technology to patients throughout the
state of Virginia," said Fred Robertson, M.D., president and CEO of
TomoTherapy. "With the installation of the TomoHD systems in these
two new cancer centers, the UVA Health System is showing its
commitment to offering the highest level of care to the broad range
of communities it serves."
About TomoTherapy Incorporated TomoTherapy
Incorporated develops, markets and sells advanced radiation therapy
solutions that can be used to treat a wide variety of cancers, from
the most common to the most complex. The ring gantry-based
TomoTherapy® platform combines integrated CT imaging with conformal
radiation therapy to deliver sophisticated radiation treatments
with speed and precision while reducing radiation exposure to
surrounding healthy tissue. TomoTherapy's suite of solutions
include its Hi-Art® treatment system, which has been used to
deliver more than three million CT-guided, helical
intensity-modulated radiation therapy (IMRT) treatment fractions;
the TomoHD™ treatment system, designed to enable cancer centers to
treat a broader patient population with a single device; and the
TomoMobile™ relocatable radiation therapy solution, designed to
improve access and availability of state-of-the-art cancer care.
TomoTherapy's stock is traded on the NASDAQ Global Select Market
under the symbol TOMO. To learn more about TomoTherapy, please
visit TomoTherapy.com.
©2011 TomoTherapy Incorporated. All rights reserved.
TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi-Art
are among trademarks, service marks or registered trademarks of
TomoTherapy Incorporated in the United States and other
countries.
Investor Contact: Thomas E. Powell Chief Financial
Officer 608.824.2800 Email Contact Media Contacts: Kevin
O'Malley Director, Corporate Communications 608.824.3384 Email
Contact Susan Lehman Rockpoint Public Relations 510.832.6006 Email
Contact
Tom Online (NASDAQ:TOMO)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Tom Online (NASDAQ:TOMO)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024